Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
I333706-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $139.90 | |
I333706-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $417.90 | |
I333706-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $625.90 | |
I333706-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $937.90 |
a compound with antibacterial properties
Synonyms | 5-((2-Cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl)pyrimidine-2,4-diamine | FT-0670272 | GTPL10820 | DTXSID70870191 | ICLAPRIM [MI] | MFCD09837803 | BCP04499 | J-515882 | A835145 | FT-0670271 | Iclaprim | Ro-482622 | RO-48-2622 | AR-100AR-100 | 5-{[(2 |
---|---|
Specifications & Purity | ≥95% |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Bacterial dihydrofolate reductase inhibitor |
Product Description | Iclaprim (AR-100) is a novel specific bacterial Dihydrofolate inhibitor. It can inhibit the growth of S. aureus (MIC90: 0.06 μg/mL). |
ALogP | 2.5 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
IUPAC Name | 5-[(2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl]pyrimidine-2,4-diamine |
---|---|
INCHI | InChI=1S/C19H22N4O3/c1-24-15-8-11(7-12-9-22-19(21)23-18(12)20)13-5-6-14(10-3-4-10)26-16(13)17(15)25-2/h5-6,8-10,14H,3-4,7H2,1-2H3,(H4,20,21,22,23) |
InChi Key | HWJPWWYTGBZDEG-UHFFFAOYSA-N |
Canonical SMILES | COC1=C(C2=C(C=CC(O2)C3CC3)C(=C1)CC4=CN=C(N=C4N)N)OC |
Isomeric SMILES | COC1=C(C2=C(C=CC(O2)C3CC3)C(=C1)CC4=CN=C(N=C4N)N)OC |
PubChem CID | 213043 |
Molecular Weight | 354.40 |
PubChem CID | 213043 |
---|---|
CAS Registry No. | 192314-93-5 |
ChEMBL Ligand | CHEMBL134561 |
Antibiotic DB | 1966 |
DrugCentral Ligand | 4573 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
G2419095 | Certificate of Analysis | Apr 18, 2024 | I333706 |
G2419096 | Certificate of Analysis | Apr 18, 2024 | I333706 |
G2419097 | Certificate of Analysis | Apr 18, 2024 | I333706 |
G2419098 | Certificate of Analysis | Apr 18, 2024 | I333706 |
G2419099 | Certificate of Analysis | Apr 18, 2024 | I333706 |
G2419100 | Certificate of Analysis | Apr 18, 2024 | I333706 |
G2419101 | Certificate of Analysis | Apr 18, 2024 | I333706 |
G2419111 | Certificate of Analysis | Apr 18, 2024 | I333706 |
Pictogram(s) | GHS08 |
---|---|
Signal | Warning |
Hazard Statements | H361:Suspected of damaging fertility or the unborn child |
Precautionary Statements | P280:Wear protective gloves/protective clothing/eye protection/face protection. P405:Store locked up. P501:Dispose of contents/container to ... P203:Obtain, read and follow all safety instructions before use. P318:if exposed or concerned, get medical advice. |
1. Sader HS, Fritsche TR, Jones RN. (2009) Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates.. Antimicrob Agents Chemother, 53 (5): (2171-5). [PMID:19289528] |
2. Huang DB, Strader CD, MacDonald JS, VanArendonk M, Peck R, Holland T. (2018) An Updated Review of Iclaprim: A Potent and Rapidly Bactericidal Antibiotic for the Treatment of Skin and Skin Structure Infections and Nosocomial Pneumonia Caused by Gram-Positive Including Multidrug-Resistant Bacteria.. Open Forum Infect Dis, 5 (2): (ofy003). [PMID:29423421] |
3. Bryant AE, Gomi S, Katahira E, Huang DB, Stevens DL. (2019) The effects of iclaprim on exotoxin production in methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.. J Med Microbiol, 68 (3): (456-466). [PMID:30676310] |